Scorpion Therapeutics’ Post

The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC: At the 2024 World Conference on Lung Cancer, Ana Baramidze, MD, PhD, presented 5-year outcomes of the trial, which investigated cemiplimab monotherapy in first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of 50% or greater. #finance #pharmacy #lifesciences

An excellent 𝑵𝒂𝒕𝒖𝒓𝒆 𝑪𝒐𝒎𝒎𝒖𝒏𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔 paper by Youya Nakazawa et al. describing yet another innovative ADC structure. In the paper the authors show preclinical efficacy in a pancreatic cancer model of an ADC composed of a BET protein-degrader 'warhead' conjugated to an anti-CEACAM6 antibody. https://lnkd.in/eUK_P294

The Evolution of ADCs in Breast Cancer: Challenges and Innovations: At the 2024 San Antonio Breast Cancer Symposium, experts discussed the development, clinical impact, and challenges of antibody-drug conjugates (ADCs). #finance #pharmacy #lifesciences

First-line treatment with ivonescimab (AK112; SMT112) monotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) monotherapy in patients with locally advanced or metastatic, PD-L1–positive non–small cell lung cancer (NSCLC), meeting the primary end point of the phase 3 HARMONi-2 trial (NCT05499390)OncLive https://lnkd.in/gj-HGWQP

Research led by our Dr. Ferdinandos Skoulidis and Dr. John Heymach demonstrates that patients with metastatic non-squamous non-small cell lung cancer harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes are more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy. "We are optimistic that these results will prompt clinicians to consider this novel therapeutic approach as a preferred treatment option," says Heymach. Read about it here. #CancerResearch #EndCancer

Great work! Important study highlighting role of CEACAM1/TIM-3 mediated immune exhaustion in cancer progression. Combined use of tamoxifen and anti-CEACAM1/TIM-3 blockade is suggested to improve outcome of immune checkpoint blockade therapy. These results are well aligned with our recent publication, wherein we highlighted the role of CEACAM1 in cancer resistance. https://lnkd.in/eA5Ckp3y

#Ivonescimab, a bispecific monoclonal antibody dual inhibitor targeting PD-1 and VEGF has shown activity in different advanced non-small cell lung cancer (NSCLC) scenarios, including EGFR mutant NSCLC after TKI failure.  Data from Phase-II AK112-201 study (NCT04736823) demonstrated clinically meaningful results for patients with advanced untreated squamous NSCLC. HARMONi-3 trial (SMT112-3003) is now available at UOMi Cancer Center for advanced untreated squamous NSCLC patients ! #LCSM #lungcancerresearch https://lnkd.in/gH3R5Y-G

𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗺𝗲𝗱𝗶𝗮𝘁𝗼𝗿 𝗼𝗳 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱! A recent study used our TRC research chemicals (TRC-M325750) and ATCC cancer cell lines to identify a critical mediator of lung cancer drug resistance. Read the findings in the journal Oncogene: https://okt.to/B0cD6m 🌟Our extensive cancer portfolio can help from target identification to drug development and manufacturing. We provide industry-leading life science tools - from biologically active small molecules to cellular models! Explore https://okt.to/Klq6g0 and https://okt.to/UW9d4m #LungCancer #ProductCitation #oncologyresearch #ResearchChemicals

Want to know more about a novel innate checkpoint #IGSF8, our clinical-stage program and the story of how we utilize #AI in this drug discovery journey? Talk to our CEO Dr. Xiaole Shirley Liu.

EML4-ALK is an oncogenic fusion protein that drives progression of ~5% of non-small cell lung cancer cases! Differential breakpoints in EML4 give rise to distinct splice variants with variant 3 (V3) being the most aggressive and resistant variant to targeted therapeutics. Check out this new paper from our lab suggesting that the Eg5 motor protein is a downstream component of a new pathway discovered in patients with EML4-ALK V3 thus, identifying a possible novel target for future treatments! https://lnkd.in/gDWTyDWt